

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Brilliant Violet 570(TM) anti-mouse/human CD44

RRID:AB_10900641

Type: Antibody

Proper Citation

BioLegend Cat# 103037, RRID:AB_10900641

Antibody Information

URL: http://antibodyregistry.org/AB_10900641

Proper Citation: BioLegend Cat# 103037, RRID:AB_10900641

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 570(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_10900641

Vendor: BioLegend

Catalog Number: 103037

Record Creation Time: 20250820T045701+0000

Record Last Update: 20250820T202231+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 570(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 570(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. Cancer immunology research, 14(1), 122.

Coulibaly ASK, et al. (2025) Id2 levels determine the development of effector vs. exhausted tissue-resident memory CD8+ T cells during CNS chronic infection. Cell reports, 44(6), 115861.

Corgnac S, et al. (2025) TGF- β and IL-12 conversely orchestrate the formation of CD103+ CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine. iScience, 28(8), 113147.

Wang Y, et al. (2025) Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting. Cell reports. Medicine, 6(8), 102250.

Ravi VR, et al. (2025) Lung CD4+ resident memory T cells use airway secretory cells to stimulate and regulate onset of allergic airway neutrophilic disease. Cell reports, 44(3), 115294.

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. Cancer cell, 43(6), 1093.

Bachem A, et al. (2025) Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma. Immunity, 58(11), 2799.

Ross RB, et al. (2024) PPAR γ Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(9), 1916.

Seldeslachts L, et al. (2024) Damping excessive viral-induced IFN- γ rescues the impaired anti-Aspergillus host immune response in influenza-associated pulmonary aspergillosis. EBioMedicine, 108, 105347.

Gadwa J, et al. (2023) Selective targeting of IL2R α combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell reports. Medicine, 4(8), 101150.

Meiser P, et al. (2023) A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. *Cancer cell*, 41(8), 1498.

Piper M, et al. (2023) Simultaneous targeting of PD-1 and IL-2R?? with radiation therapy inhibits pancreatic cancer growth and metastasis. *Cancer cell*, 41(5), 950.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. *Cell reports*, 41(3), 111478.

Hua Y, et al. (2022) Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. *Cancer cell*, 40(12), 1600.

Scheyltjens I, et al. (2022) Single-cell RNA and protein profiling of immune cells from the mouse brain and its border tissues. *Nature protocols*, 17(10), 2354.